KTTA – pasithea therapeutics corp. (US:NASDAQ)
Stock Stats
News
Pasithea Therapeutics (NASDAQ:KTTA) was upgraded by analysts at Zacks Research to a "hold" rating.
Pasithea Therapeutics (NASDAQ:KTTA) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Pasithea Therapeutics (NASDAQ:KTTA) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Pasithea Therapeutics (NASDAQ:KTTA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Form PRE 14A Pasithea Therapeutics For: Jan 28
Form 8-K Pasithea Therapeutics For: Dec 12
Form SCHEDULE 13G Pasithea Therapeutics Filed by: JANUS HENDERSON GROUP PLC
Form SCHEDULE 13G Pasithea Therapeutics Filed by: Squadron Capital Management LLC
Form SCHEDULE 13G Pasithea Therapeutics Filed by: Vivo Opportunity Fund Holdings, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.